Drug releasing coatings for medical devices

• US 8,366,660 B2
• Filed: 03/07/2011
• Issued: 02/05/2013
• Est. Priority Date: 11/20/2006
• Status: Active Grant

• Current Assignee: Lutonix, Inc. (Becton, Dickinson & Co)
• Original Assignee: Lutonix, Inc. (Becton, Dickinson & Co)
• Inventors: Wang, Lixiao
• Primary Examiner(s): ZISKA, SUZANNE E
• Application Number:
  US13/042,207
• Publication Number:
  US 20110160658A1
• Time in Patent Office: 701 Days
• Field of Search: None
• US Class Current: 604/99.04
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61L 2300/216 with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/428 Vitamins, e.g. tocopherol, riboflavin
• CPC Class Codes: A61L 2300/608 having two or more layers
• CPC Class Codes: A61L 2300/802 Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
• CPC Class Codes: A61L 2420/06 Coatings containing a mixture of two or more compounds
• CPC Class Codes: A61L 2420/08 Coatings comprising two or more layers
• CPC Class Codes: A61L 29/08 Materials for coatings
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 29/18 Materials at least partially X-ray or laser opaque
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61L 31/18 Materials at least partially X-ray or laser opaque
• CPC Class Codes: A61M 2025/105 having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
• CPC Class Codes: A61M 2210/1025 Respiratory system A61M2210/0618 take precedence
• CPC Class Codes: A61M 25/10 Balloon catheters A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02; inflatable balloons for placing stents or stent-grafts A61F2/958 ; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00
• CPC Class Codes: A61P 11/00 : Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 : Antiasthmatics
• CPC Class Codes: A61P 29/00 : Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/02 : Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 7/02 : Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system

Abstract

The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. The additive has a hydrophilic part and a hydrophobic part and the therapeutic agent is not enclosed in micelles or encapsulated in particles or controlled release carriers.

Claims

1. A balloon catheter for delivering a therapeutic agent to a target site of a blood vessel, the balloon catheter comprising:

an inflatable polyamide balloon; and

a coating layer that adheres to an exterior surface of the inflatable polyamide balloon,

wherein;

the coating layer comprises a hydrophobic therapeutic agent and at least one water-soluble additive;

the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, everolimus, docetaxel, and combinations thereof;

the hydrophobic therapeutic agent is not enclosed in micelles or liposomes and is not encapsulated in polymer particles;

the at least one water-soluble additive comprises a PEG fatty ester selected from the group consisting of PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan stearates, PEG sorbitan monolaurates, and PEG sorbitan monooleates;

the ratio by weight of the at least one additive to the therapeutic agent in the coating layer is from about 0.05 to 100.

2. The balloon catheter according to claim 1, wherein the at least one water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monostearate, and PEG-20 sorbitan monooleate.

3. The balloon catheter according to claim 1, wherein the at least one water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate and PEG-20 sorbitan monooleate.

4. The balloon catheter according to claim 3, wherein the coating layer consists essentially of the therapeutic agent and the at least one water-soluble additive.

5. The balloon catheter according to claim 1, wherein the concentration of the therapeutic agent in the coating layer is from 1 μ

g/mm² to 20 μ

g/mm².

6. The balloon catheter according to claim 1, wherein the concentration of the therapeutic agent in the coating layer is from 2 μ

g/mm² to 6 μ

g/mm².

7. The balloon catheter according to claim 1, wherein the concentration of the at least one water-soluble additive in the coating layer is from 1 μ

g/mm² to 10 μ

g/mm².

8. The balloon catheter according to claim 1, wherein the ratio by weight of the at least one water-soluble additive to the therapeutic agent in the coating layer is from about 0.1 to 5.

9. The balloon catheter according to claim 1, wherein the ratio by weight of the at least one water-soluble additive to the therapeutic agent in the coating layer is from about 0.5 to 2.

10. The balloon catheter according to claim 1, wherein the ratio by weight of the at least one water-soluble additive to the therapeutic agent in the coating layer is from about 0.8 to 1.2.

11. The balloon catheter according to claim 1, wherein the balloon catheter is a perfusion balloon catheter, a cutting balloon catheter, or a scoring balloon catheter.

12. The balloon catheter according to claim 1, further comprising a top layer overlying the surface of the coating layer to prevent loss of the hydrophobic therapeutic agent during transit of the balloon catheter through the blood vessel to the target site.

13. The balloon catheter according to claim 1, further comprising a dimethylsulfoxide solvent layer overlying the surface of the coating layer.

14. The balloon catheter according to claim 1, wherein the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, and combinations thereof.

15. The balloon catheter according to claim 1, wherein the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel and rapamycin.

16. The balloon catheter according to claim 1, wherein the hydrophobic therapeutic agent is paclitaxel.

17. The balloon catheter according to claim 1, wherein the coating layer does not include an iodine covalent bonded contrast agent, oil, or a lipid.